Pacific Biosciences Of California (PACB) EBITDA Margin Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -430.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 128.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 301.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 141.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 102.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 851.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 241.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -313.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | 113,203.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113,203.00 |
| Dec 31, 2025 | 29,786.00 |
| Sep 30, 2025 | 5,919.00 |
| Jun 30, 2025 | 37,549.00 |
| Mar 31, 2025 | -94,487.00 |
| Dec 31, 2024 | -24,012.00 |
| Sep 30, 2024 | -1,220.00 |
| Jun 30, 2024 | -33,447.00 |
| Mar 31, 2024 | 2,494.00 |
| Dec 31, 2023 | 16,835.00 |
| Sep 30, 2023 | 8,282.00 |
| Jun 30, 2023 | 3,782.00 |
| Mar 31, 2023 | -89.00 |
| Dec 31, 2022 | -13,881.00 |
| Jun 30, 2022 | -6,889.00 |
| Mar 31, 2022 | -11,744.00 |
| Dec 31, 2021 | -9,120.00 |
| Jun 30, 2021 | 1,501.00 |
| Mar 31, 2021 | 9,345.00 |
| Dec 31, 2020 | -2,421.00 |